Abstract 231P
Background
Body mass index (BMI) has shown the associated with clinical outcomes of immune checkpoint inhibitors (ICIs) treatment in patients with several malignancies. We previously reported the association between clinical outcome in advanced urothelial carcinoma (UC) patients treated with pembrolizumab and BMI according to the WHO international classification. However, no patient in our cohort was grouped into obese (BMI 30kg/m2≤) and WHO BMI classification may be unsuitable for Asians. Therefore, we investigated the association between BMI classification developed for Asian people and clinical outcomes of pembrolizumab for advanced UC.
Methods
We retrospectively reviewed consecutive patients with advanced UC who received pembrolizumab between December 2003 and March 2023. Patients were divided into three groups based on BMI classification for Asians; the non-overweight group (BMI < 22.9 kg/m2), the overweight group (23 ≤ BMI < 24.9 kg/m2), and the obese group (BMI ≥ 25 kg/m2). Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events (AEs) were compared among the groups. We additionally investigated factors associated with PFS using the multivariate analysis.
Results
Of 99 eligible patients, 54 (54.5%), 21 (21.2%) and 24 (24.2%) were in the non-overweight, overweight and obese group, respectively. PFS was significantly longer in the obese group (median 10.3 months) than that in the non-overweight (median 4.2 months) and the overweight group (median 2.3 months) (p=0.04). Multivariate analysis showed that obese was significantly associated with favorable PFS. The obese group had higher objective response rate and longer OS compared to other groups, although the difference did not reach the statistical significance. Multivariate analysis showed that obese was significantly associated with favorable PFS. There was no difference in the occurrence of irAEs among three groups.
Conclusions
BMI was associated with PFS for patients with advanced UC received pembrolizumab and BMI Asian classification may be more useful and suitable for Asian patients than that of WHO classification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract